Acura Pharmaceuticals to Host Third Quarter 2012 Financial Results Conference Call on November 7, 2012

Thu Nov 1, 2012 4:17pm EDT

* Reuters is not responsible for the content in this press release.

  PALATINE, IL, Nov 01 (Marketwire) -- 
Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical
company innovating abuse deterrent drugs, today announced that the
company plans to report financial results for the third quarter of 2012
following the close of financial markets on Tuesday, November 6, 2012.
The company will host a conference call to discuss the results on
Wednesday, November 7, 2012 at 8:30 a.m. ET.

    To participate in the live conference call, please dial 888-359-3624
(U.S. and Canada) five to ten minutes prior to the start of the call. The
participant passcode is 4454583. 

    A replay of the call will be available beginning November 8, 2012 at
11:30 a.m. ET and ending on November 20, 2012 on the company's website,
and by dialing 888-203-1112 (U.S. and Canada). The replay participant
code is 4454583.

    About Acura Pharmaceuticals
 Acura Pharmaceuticals is a specialty
pharmaceutical company engaged in the research, development and
commercialization of product candidates intended to address medication
abuse and misuse, utilizing its proprietary AVERSION(R) and IMPEDE(TM)
technologies. In June 2011, the U.S. Food and Drug Administration
approved OXECTA(R) which incorporates the AVERSION(R) technology. The
Company has a development pipeline of additional AVERSION(R) technology
products including other opioids and its IMPEDE(TM) technology for
pseudoephedrine hydrochloride products.

    The trademark OXECTA(R) is owned by Pfizer Inc.

    

Contact:
for Acura Investor Relations
investors@acurapharm.com 
847-705-7709

for Acura Media Relations
pr@acurapharm.com 
847-705-7709 

Copyright 2012, Marketwire, All rights reserved.

-0-
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.